Market open · Delayed intraday data · 3:46 PM ET
Last update: Nov 19, 2026, 3:32 PM ET
Repligen Corporation
$171.37▼ 0.75% today
Market Open

Why Repligen Corporation (RGEN) stock moved

Latest session▲ 6.5% · Nov 18, 2026 close

Why Repligen Corporation (RGEN) rose 6.5% on November 18, 2026

Repligen Corporation (RGEN) rose 6.5% on November 18, 2026, closing at $172.67 versus $162.18 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no major company-specific catalyst was found. Volume was 1.8x the 5-day average, modestly elevated; a minor institutional position establishment (Ethic Inc. acquiring ~3,054 shares) was noted but does not explain the magnitude of the move. Source: FMP price data; BestStocks detection.

Updated
Prior close
$162.18
Nov 18, 2026 close
$172.67
Change (close-to-close)
+$10.49
+6.47%
As first detected · Nov 18, 2026, 4:44 PM ET

Repligen Corporation (RGEN) moved +5.91% from $163.03 to $172.67 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no major company-specific catalyst was found. Volume was 1.8x the 5-day average, modestly elevated; a minor institutional position establishment (Ethic Inc. acquiring ~3,054 shares) was noted but does not explain the magnitude of the move.

What to watch next: Monitor for earnings on 2027-02-23 and any analyst updates ahead of that announcement.

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved RGEN

  1. −3.0%Amid broader sector softness in life sciences and biotech tools (Illumina, Revvity, ICON also lower today per web search).
  2. −3.5%Repligen Corporation (NASDAQ: RGEN) is trading down roughly 3.3% to $166.91 as of mid-morning on November 12, 2026, pulling back from its previous close of $172.62.
  3. +3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  4. −5.5%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  5. −6.2%Repligen Corporation fell 6.2% on October 30, 2026, following the announcement of a $1 billion private convertible senior notes offering due 2031, coupled with a concurrent $120 million share repurchase program. Read the October 30, 2026 analysis →
  6. +5.1%After reporting Q3 2026 earnings that beat consensus.
  7. −2.4%Repligen Corporation (RGEN) reported EPS of $0.53 vs. consensus estimate of $0.46, beating by 14.5% on 2026-10-27.
  8. −4.8%RGEN moved -3.66% from its $182.09 open to a $175.42 close on 2026-10-16.
  9. +3.4%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  10. +6.1%Repligen completed its $1.5 billion acquisition of BioLife Solutions on October 6, 2026, expanding into cell-therapy tools and biopreservation markets.
  11. −4.4%After the company completed its acquisition of BioLife Solutions.
  12. −7.7%Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing.
  13. +4.3%We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  14. −7.8%Volume of 1.47x normal suggests active selling despite the positive earnings surprise, indicating a sell-the-news or guidance-driven reaction.
  15. +3.3%Repligen Corporation (RGEN) stock is up today because it is continuing a multi-week momentum surge that pushed the stock to a new 52-week high of $190.01.While there is no new company-specific catalyst filed today, the upward movement is driven by a broader wave of investor optimism, recent Wall Street price target upgrades (including Argus raising its target to $196.00), and continued positive sentiment from its raised 2026 financial guidance and pending BioLife Solutions acquisition.

Repligen Corporation (RGEN) shares fell 0.8% to $171.37 as of November 19, 2026, a slight decline from the prior close of $172.67. BestStocks flagged the session as a major change for RGEN. The move is tied to price move up. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

RGEN fell 0.8% to $171.37

RGEN fell 0.8% in its latest session, moving from $172.67 to $171.37.

Material / EarningsWeak confidence
Rel. volume
0.4×
Below Avg
Vs peers
—
No comparable peers
Market cap
$11.0B
NASDAQ Global Select
Analyst target
$198
+15.5% vs price
Price chart
Oct 19 – Nov 19
EVNVFNEE$162$175$189Oct 19Oct 27Nov 4Nov 11Nov 19
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Repligen Corporation investors

For Repligen Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Negative session, down 0.8%. Wall Street's consensus price target sits at $198.00, implying +15.5% upside from $171.37. BestStocks rates the overall signal quality weak (32/100). With earnings roughly 96 days out, the next report is the most likely near-term test of the move.

RGEN price reaction

RGEN last traded at $171.37, down $1.30 (-0.75%) from the previous close of $172.67. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $162.18 and $188.64, and it currently sits about 35% of the way up that band.

Bullish and bearish analyst opinions on Repligen Corporation (RGEN)

The consensus analyst price target on Repligen Corporation (RGEN) is $198.00, 15.5% above the recent $171.37. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.

The bullish case

  • Wall Street's consensus price target of $198.00 implies +15.5% upside from $171.37.
  • The Street's most bullish target is $225.00 (+31.3%).
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $160.00 (-6.6%).
  • Material negative event.
  • Negative session, down 0.8%.
  • Repligen announced a $1 billion private convertible senior notes offering (Globe Newswire), triggering an 8.56% intraday decline from $188.64 to $172.49.
  • Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $198+15.5%
= 4 maintains
RBC Capital maintained Outperform · 2026-10-28
SEC filings watch
8-K2026-11-06
Material event — review for impact
high
10-Q2026-10-30
Quarterly financial results
medium
8-K2026-10-30
Material event — review for impact
high
8-K2026-10-27
Material event — review for impact
high
Peer context
RGEN-0.8%

Previous notable changes for RGEN

Valuation2026-11-12-3.5%via Yahoo Finance ↗
Repligen Corporation moved -3.26% intraday from $172.62 to $167.00. Repligen Corporation (NASDAQ: RGEN) is trading down roughly 3.3% to $166.91 as of mid-morning on November 12, 2026, pulling back from its previous close of $172.62. There is no single company-specific press release or earnings surprise driving today's drop; instead, the decline reflects valuation digestion, profit-taking after a massive six-month rally, and lingering reaction to recent debt restructuring. ### Repligen Corp (RGEN) $166.90 -3.31% today As of Nov 12, 10:40 AM EST • Disclaimer 9:30 AM 9:45 AM 10:00 AM 10:15 AM 10:30 AM 166 168 170 172 Prev close $172.62 Nov 12, 2026 9:30 AM - 10:40 AM 1D 5D 1M 6M YTD 1Y 5Y Max| Open 167.71 | Mkt cap $10.67B USD | 52-wk high 198.87 | | High 169.40 | P/E ratio- | 52-wk low 100.99 | | Low 163.85 | Div yield- | ### Key Drivers Behind the Pullback - Profit-Taking After a 54% Six-Month Rally: Between May 11 and November 9, 2026, RGEN surged 54.4% , vastly outperforming the broader S&P 500. With shares nearing multi-month highs, short-term traders have been locking in gains. - Valuation Scrutiny & Analyst Commentary: Fresh market analysis published this morning on Simply Wall St questioned whether RGEN is "fully priced" following its recent r
News2026-11-04-0.0%
Repligen CEO to participate in analyst discussion at Jefferies Global Healthcare Conference in London.
Risk2026-10-30-6.2%via globenewswire.com ↗
Repligen announced a $1 billion private convertible senior notes offering (Globe Newswire), triggering an 8.56% intraday decline from $188.64 to $172.49. Volume surged to 1.55M shares—7.71x the typical level at this stage of the session—signaling heavy seller participation.
Filings2026-10-30-6.2%
Repligen Corporation (RGEN) filed its Q3 2026 10-Q on October 30, 2026. The filing precedes earnings guidance scheduled for early November.

In-depth RGEN event analyses

Permanent, dated analyses of RGEN's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2027-02-23 (est.)
in 96 days
Earnings Release
2027-02-23
High impact
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about RGEN

Why did Repligen Corporation (RGEN) stock move?

Repligen Corporation (RGEN) rose 6.5% on November 18, 2026, closing at $172.67 versus $162.18 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no major company-specific catalyst was found. Volume was 1.8x the 5-day average, modestly elevated; a minor institutional position establishment (Ethic Inc. acquiring ~3,054 shares) was noted but does not explain the magnitude of the move. Source: FMP price data; BestStocks detection.

How much did RGEN stock fall?

RGEN lost 0.75% ($1.30) versus the prior close of $172.67, last trading at $171.37 on 0.4× average volume.

When is Repligen Corporation's next earnings date?

RGEN's next earnings report is estimated for 2027-02-23 — about 96 days away.

What is the analyst price target for RGEN?

The consensus analyst price target for RGEN is $198.00, about 15.5% above the current $171.37. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.

How BestStocks tracks RGEN

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.